69 results on '"Stevenson, John C."'
Search Results
2. Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms
3. Early menopause is associated with increased risk of arterial hypertension: A systematic review and meta-analysis
4. Is there a role for menopausal hormone therapy in a woman with increased lipoprotein (a) concentrations?
5. EMAS position statement: Predictors of premature and early natural menopause
6. Menopause and diabetes: EMAS clinical guide
7. Current management of pelvic organ prolapse in aging women: EMAS clinical guide
8. Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide
9. Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.
10. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement
11. Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Position Statement
12. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis
13. Osteoporosis management in patients with breast cancer: EMAS position statement
14. Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause
15. A model of care for healthy menopause and ageing: EMAS position statement
16. Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS)
17. EMAS recommendations for conditions in the workplace for menopausal women
18. EMAS position statement: Testosterone replacement therapy in the aging male
19. Misrepresentation of the risk of ovarian cancer among women using menopausal hormones. Spurious findings in a meta-analysis
20. The effect of menopause and gender on lipids and HDL cholesterol subfractions in apparently healthy pre- and postmenopausal women and men
21. Hormone therapies and ischemic heart disease
22. Effects of menopause, gender and age on lipids and high-density lipoprotein cholesterol subfractions
23. Erratum to “The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)” [Maturitas 79 (2014) 122–132]
24. The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
25. Corrigendum to: “Oral estradiol and dydrogesterone combination therapy in postmenopausal women: Review of efficacy and safety” [Maturitas 76 (2013) 10–21]
26. Oral estradiol and dydrogesterone combination therapy in postmenopausal women: Review of efficacy and safety
27. What constitutes healthy eating for the heart?
28. Will heartburn break your leg?
29. A woman's journey through the reproductive, transitional and postmenopausal periods of life: Impact on cardiovascular and musculo-skeletal risk and the role of estrogen replacement
30. Aspirin in the primary prevention of cardiovascular disease
31. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5mg 17β-oestradiol and 2.5mg dydrogesterone for the treatment of vasomotor symptoms: Results from a double-blind, controlled study
32. Coronary heart disease and menopause management: The swinging pendulum of HRT
33. HRT and cardiovascular disease
34. HRT and the primary prevention of cardiovascular disease
35. Justification for the use of HRT in the long-term prevention of osteoporosis
36. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy
37. Inflammation markers and erythrocyte sedimentation rate but not metabolic syndrome factor score predict coronary heart disease in high socioeconomic class males: the HDDRISC study
38. Where has WHI led us now?
39. Hormone therapy and heart disease
40. 17β-Estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women
41. Cardiovascular effects of oestrogens
42. Effects of oral and transdermal 17β-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women
43. Relation of plasma lipids to insulin resistance, nonesterified fatty acid levels, and body fat in men from three ethnic groups: Relevance to variation in risk of diabetes and coronary disease
44. Effects of equine oestrogens on markers of vasoactive function in human coronary artery endothelial cells
45. Use of Pro-Gest cream in postmenopausal women
46. The glycolytic pathway to coronary heart disease: A hypothesis
47. The effect of menopause on serum uric acid levels in non-obese healthy women
48. 17β-Oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells
49. Physiological hyperinsulinemia is not associated with alterations in venous plasma levels of endothelin-1 in healthy individuals
50. Insulin Resistance in Chronic Heart Failure: Relation to Severity and Etiology of Heart Failure
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.